BioLineRx Ltd. (TLV: BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA | Market Cap | 79.00M |
| Revenue (ttm) | 81.75M |
| Net Income (ttm) | -74.04M |
| Shares Out | 2.14B |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,423,631 |
| Average Volume | 18,626,170 |
| Open | 3.600 |
| Previous Close | 3.700 |
| Day's Range | 3.400 - 3.700 |
| 52-Week Range | 3.400 - 35.700 |
| Beta | 1.02 |
| RSI | 30.06 |
| Earnings Date | Mar 19, 2025 |
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of ski... [Read more]
News
BioLineRx announces change to ratio of ADS to ordinary shares
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, ...
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) rose sharply in today's pre-market trading after the company announced fourth-quarter results . Taiwan Semiconductor Mfg. said...
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday. The Dow traded up 0.08% to 42,765.84 while the NASDAQ gained 1.05% to 19,828.63. ...
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.
BioLineRx announces $10M registered direct offering; shares tumble
BioLineRx Announces $10 Million Registered Direct Offering
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapie...
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ETCompany ParticipantsJohn Lacey - Head of IR & Corporate...
BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M
BioLineRx press release (BLRX): Q3 GAAP EPS of $0.00 beats by $0.07. Revenue of $4.94M misses by $0.35M. As of September 30, 2024, the company had cash,
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 mi...
Earnings Scheduled For November 25, 2024
Companies Reporting Before The Bell • Alarum Technologies (NASDAQ: ALAR) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. • BioLine Rx (NASDAQ: BLRX) is expecte...
BioLineRx Q3 2024 Earnings Preview
BioLineRx (BLRX) is set to report Q3 earnings on Nov 25. Consensus estimates are -$0.11 EPS and $5.29M revenue.
BioLineRx inks licensing deal, share purchase agreement
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% ...
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a ...
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide
BioLineRx receives patent allowance for motixafortide in the U.S., extending intellectual property protection through December 2041.
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct. 16, 2024 /PRNewswire/ -- BioLineR...
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
Read about biolinerx's Q2 financial results - GAAP EPS of $0.00 and revenue of $5.39M.
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60...
biolinerx Q2 Earnings Preview
biolinerx (BLRX) to announce Q2 earnings on August 15th.
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to ex...